Home Cart Sign in  
Chemical Structure| 2152628-33-4 Chemical Structure| 2152628-33-4

Structure of Selpercatinib
CAS No.: 2152628-33-4

Chemical Structure| 2152628-33-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Selpercatinib is a potent and specific RET inhibitor with IC50 values of 1 nM, 2 nM, 2 nM, 4 nM, 2 nM, 2 nM for WT RET, RET V804M, RET V804L, RET A883F, RET M918T and RET S891A respectively.

Synonyms: LOXO-292; ARRY-192

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Zayed, Aref L ; Alshekhhossin, Aysheh M ; Al Kilani, Omar M ; Sana' ; ' ; a, A Jaber , et al.

Abstract: (RETEVMOTM) is a selective anticancer agent recently approved for thyroid and non-small cell lung cancer. Reliable analytical methods are essential for investigating its potential drug interactions. In this study, the fluorescence properties of were exploited for the first time to develop a sensitive high-performance liquid chromatography with fluorescence detection (HPLC-FLD) method to quantify in human and rat liver microsomes and rat plasma. The method was successfully validated according to M10 guidelines demonstrating excellent accuracy, precision, selectivity, and sensitivity across a concentration range of (50–2000) ng/mL in plasma samples, with a short run time of less than 4 min. The method was applied to metabolic stability studies, where exhibited moderate intrinsic clearance (CLint) in human liver microsomes (CLint of 44.9 μL/min/mg), low clearance in female rat liver microsomes (CLint 10.6 μL/min/mg), and nearly no depletion in male rat liver microsomes. After treatment with dexamethasone, the clearance of was enhanced in both female and male rat liver microsomes, suggesting potential drug-drug interaction. Dexamethasone-treated female rat liver microsomes showed clearance similar to human liver microsomes, indicating their suitability as a surrogate model for studying human metabolism in vitro. Additionally, the inhibitory effect of on metabolism was comparable in both human and dexamethasone-treated female rat liver microsomes, with IC50 values of 9.3 μM and 10.9 μM, respectively. These findings suggest the need to investigate these potential drug interactions in clinical settings, as they may affect efficacy and toxicity. This HPLC-FLD method offers a rapid, sensitive, and cost-effective alternative to LC-MS/MS for studying pharmacokinetics in various in vitro and in vivo models.

Purchased from AmBeed:

Alternative Products

Product Details of Selpercatinib

CAS No. :2152628-33-4
Formula : C29H31N7O3
M.W : 525.60
SMILES Code : N#CC1=C2C(C3=CC=C(N4CC(C5)N(CC6=CC=C(OC)N=C6)C5C4)N=C3)=CC(OCC(C)(O)C)=CN2N=C1
Synonyms :
LOXO-292; ARRY-192
MDL No. :MFCD31814089
InChI Key :XIIOFHFUYBLOLW-UHFFFAOYSA-N
Pubchem ID :134436906

Safety of Selpercatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Selpercatinib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MZCRC1 cells 4-5 μM ~50 days Analyze residual RET-altered cancer cells under prolonged RET TKI treatment, revealing that these cells can still proliferate slowly while RET kinase is inhibited. Drug Resist Updat. 2023 May;68:100958.
TT cells 4-5 μM ~50 days Analyze residual RET-altered cancer cells under prolonged RET TKI treatment, revealing that these cells can still proliferate slowly while RET kinase is inhibited. Drug Resist Updat. 2023 May;68:100958.
LC-2/ad cells 4-5 μM ~50 days Analyze residual RET-altered cancer cells under prolonged RET TKI treatment, revealing that these cells can still proliferate slowly while RET kinase is inhibited. Drug Resist Updat. 2023 May;68:100958.
TPC1 cells 4-5 μM ~50 days Analyze residual RET-altered cancer cells under prolonged RET TKI treatment, revealing that these cells can still proliferate slowly while RET kinase is inhibited. Drug Resist Updat. 2023 May;68:100958.
HEK293-OATP1B3 cells 5 μM 2.5 minutes To assess if selpercatinib is taken up by OATP1B3, results showed selpercatinib was not transported by OATP1B3 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
HEK293-OATP1B1 cells 5 μM 2.5 minutes To assess if selpercatinib is taken up by OATP1B1, results showed selpercatinib was not transported by OATP1B1 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
HEK293-OATP1A2 cells 5 μM 2.5 minutes To assess if selpercatinib is taken up by OATP1A2, results showed selpercatinib was not transported by OATP1A2 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
MDCK-II-mAbcg2 cells 5 μM 8 hours To assess if selpercatinib is transported by mAbcg2, results showed selpercatinib was efficiently transported by mAbcg2 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
MDCK-II-hABCG2 cells 5 μM 8 hours To assess if selpercatinib is transported by hABCG2, results showed selpercatinib was not transported by hABCG2 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
MDCK-II-hABCB1 cells 5 μM 8 hours To assess if selpercatinib is transported by hABCB1, results showed selpercatinib was efficiently transported by hABCB1 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
MDCK-II cells 5 μM 8 hours To assess transepithelial transport of selpercatinib, results showed selpercatinib was not transported by endogenous canine ABCB1 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
TPC1 cells 1 nM to 1 µM 72 hours Significantly decreased TPC1 cell viability with IC50 of 15 nM NPJ Precis Oncol. 2024 Feb 20;8(1):39.
Ba/F3 cells 3 nM 4 days To evaluate the inhibitory effect of Selpercatinib on the proliferation of Ba/F3 RET D898-901 and RET C634R cells JCO Precis Oncol. 2023 Aug;7:e2300052.
ECLC5-GLx cells 100 nM 6, 24, 48 hours To evaluate the combination effect of MDM2 and RET inhibitors, results showed increased p27 expression, decreased E2F1 expression, and maintained levels of p-p53 and PUMA. JCO Precis Oncol. 2024 Sep;8:e2400241.
HEK293 cells transduced with hOATP1A2 5 μM 2.5 minutes Evaluate whether selpercatinib is transported by hOATP1A2, results showed selpercatinib was not transported by hOATP1A2 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
MDCK-II cells transduced with mAbcg2 5 μM 8 hours Evaluate whether selpercatinib is transported by mAbcg2, results showed selpercatinib was efficiently transported by mAbcg2 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
MDCK-II cells transduced with hABCG2 5 μM 8 hours Evaluate whether selpercatinib is transported by hABCG2, results showed selpercatinib was not transported by hABCG2 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
MDCK-II cells transduced with hABCB1 5 μM 8 hours Evaluate whether selpercatinib is transported by hABCB1, results showed selpercatinib was efficiently transported by hABCB1 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
MDCK-II cells 5 μM 8 hours Evaluate the transepithelial transport capacity of selpercatinib, results showed selpercatinib was not transported by canine ABCB1 Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
TPC1 cells 1 nM to 1 µM 72 hours Significantly decreased TPC1 cell viability with IC50 of 15 nM NPJ Precis Oncol. 2024 Feb 20;8(1):39.
Ba/F3 cells 3 nM 4 days Evaluate the inhibitory effect of Selpercatinib on RET D898-901 and RET C634R mutant cells JCO Precis Oncol. 2023 Aug;7:e2300052.
ECLC5-GLx cells 100 nM 6, 24, 48 hours Evaluate the combination effect of MDM2 and RET inhibitors, showing synergistic activity and increased expression of proteins involved in cell cycle arrest and apoptosis. JCO Precis Oncol. 2024 Sep;8:e2400241.
Ba/F3 EML4-ALK v1 G1202R 0.1-0.8 nmol/L 72 hours Evaluate the inhibitory effect of NVL-655 on ALK G1202R mutant cells Cancer Discov. 2024 Dec 2;14(12):2367-2386.
Karpas299 2.0 nmol/L 5 days Evaluate the inhibitory effect of NVL-655 on NPM1-ALK fusion cells Cancer Discov. 2024 Dec 2;14(12):2367-2386.
MGH048-1 0.3-1.6 nmol/L 5 days Evaluate the inhibitory effect of NVL-655 on ALK fusion-positive NSCLC cells Cancer Discov. 2024 Dec 2;14(12):2367-2386.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Genetically modified mouse models Oral 10 mg/kg Single dose, 4 hours duration To assess the impact of ABCB1 and ABCG2 on selpercatinib pharmacokinetics, results showed ABCB1 and ABCG2 significantly limit brain and testis penetration of selpercatinib Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087.
Nude mice TPC1 xenograft model Oral 0.5 mg/kg/dose 4 cycles, each cycle consisting of 2-day selpercatinib treatment followed by 2-day MitoQ treatment and 1 drug holiday Selpercatinib and MitoQ combination significantly suppressed the growth of TPC1 xenografts and prolonged mouse survival NPJ Precis Oncol. 2024 Feb 20;8(1):39.
NSG mice ECLC5-GLx and LX-285 patient-derived xenograft models Oral 10 mg/kg twice daily 5 days on, 2 days off, for 62 days To evaluate the antitumor effect of Selpercatinib in combination with MDM2 inhibitors, results showed that the combination therapy was significantly superior to monotherapy, providing more durable tumor control. JCO Precis Oncol. 2024 Sep;8:e2400241.
Mouse Lu-01-0015 (HIP1-ALK PDX) Oral 1.5 mg/kg Twice daily for 14 days Evaluate the inhibitory effect of NVL-655 on ALK fusion-positive tumors in vivo Cancer Discov. 2024 Dec 2;14(12):2367-2386.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.51mL

1.90mL

0.95mL

19.03mL

3.81mL

1.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories